Please assess the completion status of the following clinical trial:

Trial Title: Anakinra in Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent provided by the patient;~* age above 18 years;~* diagnosis of hidradenitis suppurativa; and~* disease of Hurley II or III severity stage~Exclusion Criteria:~* history of systemic lupus erythematosus, of rheumatoid arthritis of of seronegative inflammatory arthritis;~* any prior administration of any type of anti-TNF therapy over the last six months;~* administration of any live (attenuated) vaccine over the last 4 weeks;~* history of recurrent vein thrombosis or embolism compatible with anti-cardiolipin syndrome;~* any present or smoldering infection;~* hepatic dysfunction defined as any value of transaminases, of γ-glutamyl transpeptidase or of bilirubin\> 2 x upper normal limit;~* history of haematological or solid tumor malignancy, arterial hypertension, liver cirrhosis, HIV infection, and hepatitis virus B or C infection~* history of episodes mimicking demyelinating disorders or a definite diagnosis of multiple sclerosis~* any creatinine value above 1.5 mg/dl~* intake of corticosteroids defined as daily intake of prednisone or equivalent more than 1mg/kg for the last three weeks;~* neutropenia defined as \<1000 neutrophils/mm3; and~* pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Water for injection (Type: PLACEBO_COMPARATOR): Placebo syringes will contain 0.67ml of sterile water for injection. This will be injected daily for 12 weeks.
- Anakinra (Type: EXPERIMENTAL): Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).